Detailed profiles of fluctuations in glucose obtained via continuous glucose monitoring highlight the complexity of glucose regulation and underscore that the definition of type 2 diabetes mellitus as a homogeneous disease is an oversimplistic approximation for a heterogeneous metabolic disorder. Whether better phenotyping would ultimately result in improved interventions and outcomes, however, remains largely unproven.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zaccardi, F., Webb, D. R., Yates, T. & Davies, M. J. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad. Med. J. 92, 63–69 (2016).
Mostafa, S. A. et al. The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting Type 2 diabetes mellitus. Diabet. Med. 27, 762–769 (2010).
Gale, E. A. Is type 2 diabetes a category error? Lancet 381, 1956–1957 (2013).
Ahlqvist, E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, 361–369 (2018).
Zaccardi, F., Pitocco, D. & Ghirlanda, G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab. Res. Rev. 25, 199–207 (2009).
Hall, H. et al. Glucotypes reveal new patterns of glucose dysregulation. PLOS Biol. 16, e2005143 (2018).
Gregg, E. W. & Wing, R. Looking again at the Look AHEAD study. Lancet Diabetes Endocrinol. 5, 763–764 (2017).
Griffin, S. J. et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378, 156–167 (2011).
Gloyn, A. L. & Drucker, D. J. Precision medicine in the management of type 2 diabetes. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(18)30052-4 (2018).
Psaty, B. M., Dekkers, O. M. & Cooper, R. S. Comparison of 2 treatment models: precision medicine and preventive medicine. JAMA https://doi.org/10.1001/jama.2018.8377 (2018).
Acknowledgements
F.Z. is funded and acknowledges support from an unrestricted educational grant from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (CLAHRC) East Midlands to the University of Leicester.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.K. has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi–Aventis, Eli Lilly and Merck Sharp & Dohme and has received grants in support of investigator and investigator-initiated trials from AstraZeneca, Novartis, Novo Nordisk, Sanofi–Aventis, Eli Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme.
Rights and permissions
About this article
Cite this article
Zaccardi, F., Khunti, K. Glucose dysregulation phenotypes — time to improve outcomes. Nat Rev Endocrinol 14, 632–633 (2018). https://doi.org/10.1038/s41574-018-0092-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-018-0092-3
This article is cited by
-
Neue Muster der Glukosedysregulation
Der Diabetologe (2019)
